Stephen Mahoney is the President, Chief Executive Officer, and Director at Viridian Therapeutics, Inc., a biotechnology company focused on developing treatments for serious and rare diseases. With over 25 years of experience in the biopharmaceutical industry, Mahoney has a proven track record of leading successful organizations and driving innovation. Prior to joining Viridian Therapeutics, he served as the President and CEO of HemoShear Therapeutics, where he played a pivotal role in advancing the company's drug discovery platform and building strategic partnerships. Mahoney's career also includes significant leadership positions at Teva Pharmaceuticals, where he served as the Senior Vice President and Chief Operating Officer of Teva's global specialty medicines business. During his tenure, he was instrumental in expanding the company's portfolio and enhancing its operational efficiency. Earlier in his career, Mahoney held various roles at Novartis, including Vice President of Sales and Marketing for the company's oncology division, where he led the successful launch of several blockbuster products. As the President, CEO, and Director at Viridian Therapeutics, Stephen Mahoney is responsible for overseeing the company's overall strategy, operations, and growth. Under his leadership, Viridian has made significant progress in advancing its pipeline of novel therapies, particularly in the areas of autoimmune and rare diseases. Mahoney's strategic vision and deep industry expertise have been crucial in positioning Viridian as a leader in the development of innovative treatments, and his commitment to improving patient outcomes continues to drive the company's mission forward.